microRNA-151检测用于评价卵巢癌铂类药物疗效的临床价值

摘要

Aim:To investigate the clinical value of microRNA-151 in evaluating effect of platinum drugs on patients with ovarian cancer .Methods:Eighty-eight ovarian cancer patients treated with platinum drugs were allocated into sensitive group and insensitive group according to the result of ATP-TCA test.MicroRNA microarray was used to detect the change of microRNA expression between two groups and the results was proven by qRT-PCR.The clinical value of detecting microR-NA-151 was estimated by ROC curves.Furthermore, SKOV3 cells were cultured in vitro and transfected with pcDNA 3.1-microRNA-151 or empty pcDNA3.1.Non-transfected SKOV3 cells and transfected SKOV3 cells were treated with 3μmol/L cisplatin for 48 h and CCK-8 assay was used to calculate the viability of different cells .Finally, the Bcl-2 expression change induced by microRNA-151 was confirmed by qRT-PCR and Western blot .Results:Compared with sensitive group , in insensitive group ,5 kinds of microRNA expression were decreased and 5 were increased .ROC curves supported that mi-croRNA-151 had effectively clinical value to assess the sensitivity of ovarian cancer patients to platinum drugs ( AUC =0.719, 95%CI=0.607-0.831).High-expressed microRNA-151 was a risk factor for ovarian cancer patients to induce resistance to platinum drugs;moreover , high-expressed microRNA-151 could induce the resistance of SKOV 3 cells to plati-num drugs and increase Bcl-2 expression(P<0.05).Conclusion:MicroRNA-151 could be used to evaluate the sensitivity of ovarian cancer patients to platinum drugs .%目的：探讨microRNA检测用于评价卵巢癌患者铂类药物疗效的临床价值。方法：研究纳入接受顺铂化疗的初治卵巢癌患者88例，根据ATP-TCA结果分为敏感组（45例）和耐药组（43例）。 microRNA微阵列分析2组患者血清microRNA表达的差异，并使用qRT-PCR加以验证。绘制ROC曲线，分析microRNA-151高表达与卵巢癌化疗不敏感现象的关系。体外培养SKOV3细胞并转染 pcDNA3．1-microRNA-151或 pcDNA3．1空质粒，使用3μmol／L顺铂处理细胞48 h，计算细胞存活率，同时采用qRT-PCR及Western blot 检测microRNA-151对细胞Bcl-2表达的影响。结果：与敏感组患者相比，耐药组患者中有5种microRNA表达上调，5种microRNA表达下调。 mi-croRNA-151水平的检测对于评价卵巢癌患者铂类药物疗效有临床价值（AUC＝0．719，95％CI＝0．607～0．831），高microRNA-151水平的患者发生对铂类药物不敏感的风险较高。高表达microRNA-151可减弱SKOV3细胞对铂类药物的敏感性，提高Bcl-2的表达（P均＜0．05）。结论：检测microRNA-151水平可以评估卵巢癌患者对铂类药物的敏感性。